glp-1 dialysis receptor agonists in patients with chronic kidney disease and either overweight or obesity GLP-1 Receptor Agonist Use in
Description
Levels of key nutrients and ingredients such as zinc, magnesium, iron and protein have declined
Individual results vary
Retatrutide showed up to 28.3% weight loss in Phase 3 trials but is not yet FDA approved
Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer's direct-to-patient expansion to date.
Learn more about its role in diabetes management.
